Biotech Cos. Say Cancer-Killing Cell IP Fight Can Be Litigated
A California immunotherapy company argued Tuesday that it can't be forced to arbitrate a fee dispute stemming from a license agreement for a special line of cancer-killing cells, urging a federal...To view the full article, register now.
Already a subscriber? Click here to view full article